10X GENOMICS INC-CLASS A (NASDAQ:TXG) reported its fourth-quarter and full-year 2025 financial results after the market close on February 12, 2026, delivering a mixed performance that has elicited a cautiously positive initial reaction from investors.
The company, a leader in single cell and spatial biology tools for life sciences research, managed to surpass analyst expectations on both the top and bottom lines for the quarter. However, the underlying growth narrative and forward-looking guidance present a more complex picture for the year ahead.
Q4 2025: Earnings and Revenue Beat
The core takeaway from the quarterly report is that 10x Genomics executed effectively against near-term expectations. The company's financial performance for the three months ending December 31, 2025, exceeded the consensus forecasts provided by Wall Street analysts.
- Revenue: Reported revenue was $166.0 million, slightly above the analyst estimate of approximately $160.9 million. It is important to note that this figure represents essentially flat growth compared to the $166.0 million reported in the fourth quarter of 2024.
- Earnings Per Share (EPS): The company reported a non-GAAP loss per share of ($0.13), which was a significant improvement over the estimated loss of ($0.21). This represents a beat of roughly 38%, indicating better-than-anticipated cost management or operational efficiency during the period.
Market Reaction and Price Action
Following the earnings release, shares of 10x Genomics traded higher in after-hours activity, reflecting investor approval of the earnings beat. The stock's performance over recent weeks, however, tells a broader story of investor sentiment leading up to the report.
- Immediate Reaction (After-Market): The stock was up approximately +2.8% in post-market trading, a direct positive response to the quarterly results.
- Recent Weakness: This uptick contrasts with a challenging month for the stock. In the four weeks preceding the earnings release, TXG shares declined by roughly -16.3%, potentially reflecting market concerns or a broader sector downturn ahead of the financial update.
- Context: The positive after-hours move suggests the earnings beat may have alleviated some of the recent pessimism, though it only partially offsets the prior month's decline.
Forward Outlook and Analyst Estimates
A critical component of the report was the company's financial outlook for 2026. 10x Genomics provided its own revenue guidance, which can be compared to existing analyst projections for the coming year.
- Company's 2026 Revenue Outlook: Management expects full-year 2026 revenue to be approximately $612.5 million.
- Analyst Consensus for 2026: Prior to the report, the analyst consensus estimate for 2026 sales stood at about $617.4 million.
- Comparison: The company's guidance of $612.5 million is slightly below the current analyst consensus, which may temper some growth enthusiasm. For the upcoming first quarter of 2026, analysts had been expecting revenue of approximately $144.7 million.
Summary of Key Announcements
Beyond the raw financial numbers, the press release underscored 10x Genomics' ongoing strategic focus. The company continues to position itself at the forefront of spatial and single-cell biology, with platforms like Chromium, Visium, and Xenium. The full-year 2025 results cap a year of execution, but the flat year-over-year Q4 revenue and the slightly conservative 2026 outlook highlight the competitive and funding environment in the life science tools sector. Investors are balancing the solid quarterly beat against the challenges of reigniting stronger top-line growth.
For a detailed breakdown of historical earnings, future estimates, and analyst revisions, you can review the data here: TXG Earnings & Estimates.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation to buy or sell any security, or an endorsement of any investment strategy. The information presented is based on publicly available data and earnings reports. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.